Learn More
e14114 Background: This clinical study with MGN1703 was started after a phase I clinical study provided clear evidence that the investigational drug is safe and well tolerated by patients with(More)
A. Stein1, D. Atanackovic2, J. Stoehlmacher3, B. Hildebrandt4, P. Stübs5, C. Steffens6, W. Brugger7, G. Hapke8, G. Illerhaus9, E. Bluemner10, C. Bokemeyer11 University Cancer Center Hamburg(More)
  • 1